The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, J.
Right arrow Articles by Li, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, J.
Right arrow Articles by Li, Z.
The Journal of Immunology, 2007, 178: 3219-3225.
Copyright © 2007 by The American Association of Immunologists, Inc.

TLR4 Hyperresponsiveness via Cell Surface Expression of Heat Shock Protein gp96 Potentiates Suppressive Function of Regulatory T Cells1

Jie Dai*, Bei Liu*, Soo Mun Ngoi*, Shaoli Sun{dagger}, Anthony T. Vella* and Zihai Li2,*

* Department of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030; and {dagger} Dianon Systems, Stratford, CT 06615


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
As one of the main mediators of the endoplasmic reticulum unfolded protein response, heat shock protein gp96 is also an obligate chaperone for multiple TLRs including TLR4. We demonstrated recently that enforced cell surface expression of gp96 in a transgenic (Tg) mouse (96tm-Tg) conferred hyperresponsiveness to LPS and induced TLR4-dependent lupus-like autoimmune diseases. In this study, we investigated the function of CD4+CD25+ Foxp3+ regulatory T cells (Treg) in these mice in light of the important roles of Treg in the maintenance of peripheral tolerance against self-Ag as well as the increasing appreciation of TLR signaling on the regulation of Treg. We found that the development of Treg was not impaired in 96tm-Tg mice. Contrary to the prediction of dampened Treg activity, we discovered that the suppressive functions of Treg were increased in 96tm-Tg mice. Inactivation of Treg during the neonatal stage of life exacerbated not only organ-specific diseases but also systemic autoimmune diseases. By crossing 96tm-Tg mice into the TLR4 null background, we demonstrated the critical roles of TLR4 in the amplification of Treg suppressive function. These findings illustrate that gp96 plays dual roles in regulating immune responses by augmenting proinflammatory responses and inducing Treg function, both of which are dependent on its ability to chaperone TLR4. Our study provides strong support to the notion of compensatory Treg activation by TLR ligation to dampen inflammation and autoimmune diseases.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
It has been shown that CD4+CD25+ regulatory T cells (Treg)3 play important roles in peripheral T cell tolerance by suppressing self-reactive immune responses, regulating antitumor immunity, and fine tuning inflammatory responses to pathogens (1, 2). Much progress has been made regarding the ontogeny and phenotype of Treg. Foxp3, a member of the forkhead/winged-helix family of transcriptional regulators, is uniquely expressed by the Treg and is the master developmental factor for the generation of Treg (3) through cooperation with NFAT (4). The NFAT connection explains the need for both IL-2 (5) and CD28 signaling (6) in the generation of functional Treg.

The mechanism by which Treg is functionally regulated remains unclear. Treg express variable levels of CTLA-4, glucocorticoid-induced TNFR-related gene product (GITR), TGF-beta, IL-10, and other molecules (1). In vitro, the suppressive functions of Treg are dependent on cell-cell contact between Treg and CD4+CD25 effector T cells (Teff) and independent of soluble factors, such as IL-10 and TGF-beta (1). However, TGF-beta and IL-10 are required for the inhibitory function of Treg in vivo (7). The roles of CTLA-4 and GITR have also been implicated as mediators of Treg function (7, 8). Recently, it was found that TGF-beta induces the generation of Foxp3+ Treg, which were completely inhibited by a proinflammatory cytokine IL-6 (9).

TLRs are important pattern recognition receptors for host to recognize and respond to pathogen-associated molecular patterns such as LPS (10). The folding and surface expression of TLR1, TLR2, and TLR4 are dependent on an endoplasmic reticulum chaperone gp96 (11). TLR ligation is generally thought to suppress Treg function (12). Two categories of TLR activity that down-regulate the function of Treg have been discovered: suppression of Treg by direct ligation of TLR8 (13) and TLR2 (14, 15) on Treg; and blunting Treg function in a TLR4-dependent fashion by rendering Teff less responsive to Treg (16). In this regard, suppression of Treg was believed to be essential for the initiation of the adaptive immune response.

Paradoxically, ligation of TLR4 (17, 18) and TLR5 (19) on Treg was recently reported to have an opposite enhancing effect on the function of Treg. In addition, antagonizing MD1 was also found to decrease the threshold of LPS activation of dendritic cells (DC) and to enhance the induction of Treg (20). The Treg-amplifying effect of TLR activation in this situation could potentially play critical roles in curtailing a late-phase immune response when an infection is contained and thus provide a feedback inhibition mechanism against TLR-dependent inflammatory process. However, direct effect of TLR4 ligation on Treg has been challenged (14, 19, 21, 22, 23). More importantly, it is unclear whether TLR4 amplification in vivo could lead to enhanced Treg function.

We previously reported that enforced cell surface expression of gp96 (96tm) in an otherwise non-autoimmune prone C57BL/6 mice induces systemic lupus-like autoimmune diseases (24). Furthermore, we found that 96tm expression confers hyperresponsiveness to LPS and the spectrum of autoimmunity in 96tm-transgenic (Tg) mice is completely abrogated in the absence of TLR4 (25). In this study, we addressed two interrelated questions. First, what is the impact of TLR4 hyperfunction on the function of Treg in vivo? Second, to what extent does Treg functional alteration, if any, contribute to the development of systemic autoimmune diseases in 96tm-Tg mice? We provide in vivo and in vitro evidence that surface expression of gp96 enhanced suppressive Treg function, which attenuated autoimmunity as inactivation of Treg during neonatal stage of life exacerbated autoimmune diseases in 96tm-Tg mice. More importantly, we discovered that gp96-mediated enhancement of Treg function was dependent on TLR4. Our study is the first example of curtailing TLR4 hyperactivation via Treg on the organismal level to prevent systemic autoimmune diseases, thus providing strong support to the notion of compensatory Treg activation by TLR ligation to dampen inflammation.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Mice

Membrane-bound gp96 Tg (96tm-Tg) mice were generated as previously described (24). C57BL/6 mice were purchased from The Jackson Laboratory. TLR4–/– mice were provided by Dr. R. Medzhitov (Yale University, New Haven, CT). Mice were maintained by the Center for Laboratory Animal Care of the University of Connecticut Health Center (Farmington, CT) according to the established guidelines (Guide for the Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources Commission on Life Sciences).

Abs and other reagents

All Abs used for flow cytometry were from BD Pharmingen or eBioscience, unless otherwise stated. Anti-CD25 Ab (clone PC61) was obtained from American Type Culture Collection. FITC-labeled anti-CD25 Ab (clone 7D4) was used to confirm the inactivation efficiency of CD4+CD25+ T cells.

Flow cytometry

Briefly, cells were washed with staining buffer (cold PBS plus 2% heat-inactivated FCS), blocked on ice with a purified anti-Fc{gamma}RII/RIII Ab (clone 93; eBioscience) for 10 min, followed by staining with various fluorochrome-conjugated Ab against interested surface markers. After staining, cells were then washed and analyzed on FACSCalibur (BD Biosciences). Dead cells were gated out by propidium iodide exclusion. For intracellular staining, cell surface markers were first stained as described, followed by fixation in 2% formaldehyde buffered with PBS, washing and permeabilization with 0.25% saponin in the staining buffer. Further staining was done using fluorochrome-conjugated Ab against respective intracellular proteins. In some experiments, cells were activated in vitro with 50 ng/ml PMA and 1 µg/ml ionomycin for 5 h in the presence of 10 µg/ml brefeldin A (Sigma-Aldrich).

In vitro suppression assay

CD4+CD25+ Treg and CD4+CD25 Teff were purified using the Regulatory T Cell Purification kit (Miltenyi Biotec) according to the manufacturer’s protocol. CD4-depleted splenocytes were irradiated (3000 rad) and used as APCs. In 96-well round-bottom plates, each well contained 5 x 104 Teff, 5 x 104 APCs, titrated number of Treg, in the presence or absence of soluble anti-CD3{epsilon} Ab (2.5 µg/ml). Cells were cultured at 37°C for 72 h. During the last 6 h, cells were pulsed with 1 µCi of [3H]thymidine, harvested by an automated 96-well plate harvester, and the cpm were determined by an automated liquid scintillation counter (Microplate Scintillation and Luminescence Counter; Packard Instrument). The suppression index was calculated as [CPM(Teff without Treg) – CPM(Teff with Treg)]/CPM(Teff without Treg) x 100%.

Determination of staphylococcal enterotoxin A (SEA)-specific CD4+ T cell response

Mice were treated with either control IgG or PC61 (anti-CD25) 3 days before immunization. Inactivation efficacy was verified by flow cytometry using anti-CD25 (7D4) Ab recognizing a different epitope from PC61. One day after i.p. injection of 1 µg of SEA, 25 µg of LPS (from Salmonella typhimurium; Sigma-Aldrich) was administered at the same route. Mice were bled for the kinetic analysis of SEA-specific Vbeta3+ CD4+ T cells as well as control Vbeta14+ CD4+ T cells in peripheral blood. At day 16, mice were sacrificed, and the percentage and the absolute number of SEA-selective and nonselective CD4+ T cells was determined from various organs.

Inactivation of Treg during the neonatal stage of life

Newborn mice were treated with PC61 Abs (500 µg) or control rat IgG by i.p. injection every 4 days for four doses, starting before 9 days of age until day 21. Antinuclear Ab (ANA) was tested using sera obtained at weeks 8, 10, and 12. Mice were sacrificed 5 mo later, for evaluation of disease and serum level of cytokines.

ELISA

ELISA was used for the quantification of serum cytokines (BD Pharmingen) according to the manufacturer’s protocol.

Histology

Various organs were fixed in 4% formaldehyde buffered with PBS. The 5-µm sections were cut using Shandon Cryotome E (Thermo Electron), stained with H&E by standard methods, and examined by a light microscopy. The evaluation was performed by single blind testing, and the severity of the gastritis was scored as follows: 0 (no inflammation), 1 (mild lymphocytic infiltration), 2 (moderate lymphocytic infiltration), or 3 (severe lymphocytic and neutrophil infiltration).

Immunofluorescence detection of glomerulonephritis and clinical evaluation of the severity of kidney disease

Samples of 5-µm cryosections of kidneys were incubated with blocking reagent (Vector Laboratories), stained with biotinylated anti-mouse IgG followed by FITC-conjugated streptavidin. Each sample was examined under a fluorescent microscope. Every glomerulus was assigned a number for its fluorescence intensity as follows: 0 (negative), 1 (slight staining), 2 (moderate staining), or 3 (bright staining). Based on an average of 83.5 ± 20.3 glomeruli evaluated per mouse (mean ± SD, obtained from a total of 40 mice), the mean fluorescence intensity was calculated as the index for the disease severity.

Detection of ANA

HEp-2-coated slides (INOVA Diagnostics) were incubated with diluted sera, followed by FITC-conjugated goat anti-mouse Ig, and examined by a fluorescence microscopy. The fluorescence staining intensity was graded as 0 (negative), 1 (slight staining), 2 (moderate staining), and 3 (bright staining). The mean fluorescence intensity was calculated.

RT-PCR

Total RNA was extracted from purified wild-type (WT) or 96tm-Tg Treg using a NucleoSpin RNA II kit (with DNase I on-column digestion), according to the manufacturer’s protocol (Clontech Laboratories). Total RNA was reverse transcribed using Superscript II and oligo(dT)12–18 primer (Invitrogen Life Technologies) per the manufacturer’s protocol. The resulting cDNA obtained from 200 ng of total RNA was amplified for genes of interests for 35 cycles, using the following primers: gp96 (forward) 5'-ccttgacattggttattgacg-3', (reverse) 5'-ccttctcggcttttacccagg-3'; 96tm (forward) 5'-acaccaaggcgtatggagat-3', (reverse) 5'-gatgatggtgagcaccaccag-3'; and beta-actin (forward) 5'-tcagaaggactcctatgtgg-3', (reverse) 5'-tctctttgatgacacgcacg-3'.

Statistical analysis

Student’s t test or Mann-Whitney U test was used for the statistical analysis by Prism software (GraphPad software). General linear model univariate and multivariate analysis were performed using SPSS 12.0 software. Values of p < 0.05 were considered statistically significantly different.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Normal development of 96tm-Tg Foxp3+ Treg

Both male and female 96tm-Tg mice developed the serological/histological evidence of autoimmunity around 4 mo. To understand the possible involvement of Treg in the pathogenesis of autoimmunity, we first analyzed Treg in 5-mo-old 96tm-Tg mice and age- and gender-matched WT mice to determine whether there was any developmental alteration of Treg in 96tm-Tg mice. By intracellular staining for Foxp3 protein, the best marker for CD4+CD25+ natural Treg, we determined the percentage and absolute number of Treg in the spleen and thymus of both WT and 96tm-Tg mice (3). We found that within the CD4+CD8 single-positive population, ~7% cells expressed surface CD25 (Fig. 1A) and 2–3% were CD4+ Foxp3+ T cells in both Tg and WT mice (Fig. 1B). No Foxp3 positivity was found in CD4 populations. Similar to thymocyte Treg distribution, splenic CD4+CD25+ populations were comparable between WT and Tg mice, either in percentage (Fig. 1C) or in absolute number (data not shown). Most of these cells were phenotypically Treg as over 80% of them were also positive for Foxp3 (data not shown). Fewer than ~5% of CD4+CD25 splenocytes were Foxp3+. Tg CD4+CD25+ T cells expressed similar levels of GITR on their cell surface (Fig. 1C), although no surface CTLA-4 or TGF-beta was detectable on unstimulated splenic CD4+CD25+ T cells from either WT or 96tm-Tg mice (data not shown). The total number of CD4+ Foxp3+ cells in the spleen was the same between WT and Tg mice, although the percentage of CD4+ Foxp3+ T cells in the spleen of 96tm-Tg mice was slightly reduced (Fig. 1D).


Figure 1
View larger version (39K):
[in this window]
[in a new window]

 
FIGURE 1. Phenotypic comparison between WT and 96tm-Tg Treg. A and B, Thymocytes from 5-mo-old WT and 96tm-Tg mice were subjected to flow cytometric analysis. CD4+CD8 single-positive populations were gated on. A, Surface staining of CD25 marker gated on propidium iodide (PI) populations. B, Intracellular staining for Foxp3. C and D, Flow cytometric analysis of splenocytes from 5-mo-old mice. C, Surface staining of CD25 or GITR gated on PI populations. D, Intracellular staining of Foxp3. IgG2a and IgG2b represent isotype controls for Ab against Foxp3 and GITR respectively. Data of one representative mouse from more than six mice in several independent experiments is shown.

 
To gauge possible functional differences between Tg and WT Treg, we next activated splenocytes with polyclonal activators PMA and ionomycin for 5 h, followed by intracellular staining for a variety of cytokines including IL-10, IL-2, IL-6, IFN-{gamma}, IL-4, and TNF-{alpha}. Under this condition, neither WT nor Tg CD4+CD25+ Treg produced a substantial level of cytokines, although both WT and 96tm CD4+CD25 cells made an appreciable amount of TNF-{alpha} and IL-2. The cytokine profile of CD4+CD25 population from Tg and WT mice appeared to be similar (Fig. 2). Taken together, we conclude that there is no significant impact either positively or negatively by 96tm on the development of Treg.


Figure 2
View larger version (22K):
[in this window]
[in a new window]

 
FIGURE 2. Cytokine profile of WT and 96tm-Tg splenocytes after polyclonal activation in vitro. Splenocytes from 5-mo-old WT and 96tm-Tg mice were incubated with PMA/ionomycin for 5 h in the presence of brefeldin A. Intracellular staining of individual cytokine and respective isotype controls were performed after surface staining of CD4 and CD25. Data of one representative mouse from three mice is shown for all, except that the staining for IL-10, and its isotype control represents analysis of 12 mice.

 
Augmented regulatory function of 96tm-Tg Treg

Next, we performed functional analysis of Treg from WT and Tg mice using a standard in vitro suppression assay to determine whether 96tm Treg retains suppressive function. CD4+CD25+ Treg were purified from the WT and Tg splenocytes by sequential negative (CD4 lineage mixture) and positive (CD25+) selections, which were then cocultivated with CD4+CD25 Teff in the presence of splenic APCs (CD4+ T cell-depleted populations) and soluble anti-CD3{epsilon} Ab for 3 days. T cell proliferation was indexed by [3H]thymidine incorporation during the last 6 h of culture. In the absence of Treg, both WT and Tg Teff proliferated robustly (Fig. 3, A and B). In contrast, neither WT nor Tg Treg divided, which is in agreement with the anergic property of Treg in vitro (1). The proliferation of Teff was greatly reduced in the presence of either WT or Tg Treg at 1:10 or 1:1 ratio (Fig. 3, A and B). The suppressive function of 96tm-Tg Treg was significantly more pronounced than that of WT Treg on the per cell basis, regardless whether Teff and APCs were of WT or Tg origin in these assays (Fig. 3).


Figure 3
View larger version (33K):
[in this window]
[in a new window]

 
FIGURE 3. Increased suppressive function of CD4+CD25+ splenic Treg in 96tm-Tg mice in vitro. CD4+CD25+ Treg were purified from WT or 96tm-Tg splenocytes, respectively. A total of 5 x 104 CD4+CD25 Teff were cocultured in the presence of soluble anti-CD3{epsilon} mAb for 72 h with medium, 0.5 x 104 (1:10) or 5 x 104 (1:1) Treg. [3H]Thymidine was added during the last 6 h. A, A total of 5 x 104 CD4-depleted splenocytes from WT mice were used as APCs. B, A total of 5 x 104 CD4-depleted splenocytes from 96tm-Tg mice served as APCs. At least three independent experiments were performed with the similar findings. Error bars represent SD. C, Comparisons of suppressive function between WT and 96tm-Tg Treg from young and old mice. Proliferation obtained in the absence of anti-CD3{epsilon} mAb was generally under 200 cpm (data not shown). Symbols represent results from one individual experiment with Treg purified from the pooled splenocytes of two to three mice. The bars represent the mean values.

 
The experiments were performed using mice that were at least 4-mo-old when autoimmune disease was already detectable serologically. The functional alteration of Treg in 96tm-Tg mice might be affected by the pathological state of these mice. Furthermore, it was reported that aging had a significant negative effect on the inhibitory functions of mouse and human Treg (8, 26, 27). To determine the impact of age and disease on the functional differences between WT and Tg Treg, we examined the suppressive functions of Treg at 6–8 wk of age when none of the WT and Tg mice had signs of autoimmunity. We found that there was already a trend of increased Treg function from 96tm-Tg mice at the young and predisease stage (Fig. 3C). The fact that there was no age-dependent decline of Tg Treg function further reinforced the notion that the expression of cell surface gp96 potentiates the function of Treg.

Regulatory effects of 96tm-Tg Treg on Teff in vivo

If Treg is hyperfunctional in 96tm-Tg mice in vivo, inactivation of Treg might lead to more robust immune responses. To test this possibility, we kinetically analyzed the expansion of endogenous SEA-specific CD4+ T cells after immunization with SEA, using low-dose LPS (25 µg) as an adjuvant (28, 29), in the presence or absence of functional Treg. We injected mice with the mAb PC61, which recognizes the {alpha}-chain of the IL-2R, CD25; this Ab is known to specifically deplete Treg (30, 31, 32, 33). The report of inactivation rather than depletion of the CD4+CD25+ Treg in vivo by anti-CD25 Ab (34) was most likely related to distinct Ag specificity of anti-CD25 Ab (32, 33). PC61 was i.p. administered 3 days before SEA immunization. SEA-specific Vbeta3+ CD4+ T cells in the peripheral blood were analyzed by flow cytometry (Fig. 4A). The kinetics of the expansion of WT and Tg SEA-specific Vbeta3+ CD4+ T cells mirrored each other well when Treg was unmanipulated. In the absence of functional Treg, the Ag-specific Vbeta3+ CD4+ T cells expanded much more in both WT and Tg mice, but the magnitude of expansion of Vbeta3+ CD4+ T cells from 96tm-Tg mice were substantially greater than WT Vbeta3+ CD4+ T cells (p = 0.049 by univariate regression analysis) (Fig. 4A). Furthermore, the increased percentages of Ag-specific Vbeta3+ CD4+ T cells were also found in other lymphoid compartments, such as spleen (p = 0.005 by multivariate analysis) or inguinal, auxiliary, and cervical lymph nodes (p = 0.006) and mesenteric lymph nodes (p = 0.008) (Fig. 4C). In contrast, non-SEA-specific Vbeta14+ CD4+ T cells in peripheral blood as well as lymph nodes remained constant in either WT or Tg mice (Fig. 4, B and D). Our data demonstrated that Tg Treg were not only hyperfunctional in vitro, but also exerted significantly more suppressive regulatory functions on the expansion of CD4+ Teff in vivo.


Figure 4
View larger version (26K):
[in this window]
[in a new window]

 
FIGURE 4. Increased expansion of Ag-specific CD4+ T cells after in vivo inactivation of Treg. Mice were injected i.p. with PC61 or control IgG before immunization with SEA plus LPS. PBL were subject to flow cytometry after staining with CD4 and TCR Vbeta3 (A) or with CD4 and TCR Vbeta14 (B) at different time points. *, p < 0.05. Splenocytes, mesenteric lymph nodes (MLN), and pooled cervical, inguinal and auxiliary lymph nodes (sLN) were also analyzed on day 16 to determine the percentage of Vbeta3 (C) or Vbeta14 (D) CD4+ T cells. **, p < 0.01. Two independent experiments with three to four mice in each group were performed with similar results. The error bars represent the SEM of at least three mice per group.

 
Exacerbation of autoimmunity in 96tm-Tg mice by inactivation of Treg

Having observed the increased suppressive function of Tg Treg in vitro and their regulatory roles in vivo, we hypothesized that Treg in 96tm-Tg mice represented a significant brake on the development of autoimmune diseases. If so, removal of such a brake might lead to exacerbation of systemic autoimmunity. We tested this hypothesis by injecting PC61 into 96tm-Tg mice beginning at the neonatal stage (within 9 days after birth) every 4 days for four injections. Down-regulation of CD25 was confirmed by flow cytometric analysis of peripheral blood 4 days after the last PC61 injection (data not shown). Inactivation of Treg by this method was transient when PC61 was given neonatally. All mice fully recovered the number of Treg in the peripheral blood as early as 1 wk after the last PC61 injection. PC61-treated 96tm-Tg mice were sacrificed at 5 mo for analysis of autoimmune disease, at which point the distribution of CD4+ T cells, CD8+ T cells, and B cells were comparable between mice treated with PC61 and mice treated with control Ig (data not shown). The percentage and cellularity of Treg also returned normal (data not shown).

However, PC61-treated 96tm-Tg mice manifested a significant exacerbation of autoimmunity by the appearance of ANA at least 2 wk earlier (age 10 wk) than control Ig-treated mice (age 12 wk or older) (Fig. 5A) and the worsening of their immune complex-mediated glomerulonephritis (Fig. 5B). Furthermore, we found that the serum level of IL-12/IL-23 p40 subunit was significantly increased in PC61-treated mice (Fig. 5C), whereas serum IL-1beta, TNF-{alpha}, and IL-6 remained undetectable in mice treated with PC61 or control Ig (data not shown). Given our recent finding that IL-12 was pathological in the lupus-like autoimmune diseases in 96tm-Tg mice (35), we conclude that Treg inactivation in 96tm-Tg mice accelerates systemic autoimmune diseases.


Figure 5
View larger version (15K):
[in this window]
[in a new window]

 
FIGURE 5. Exacerbation of autoimmune diseases in 96tm-Tg mice after functional inactivation of Treg during their neonatal lives. Newborn mice (within 9 days after birth) were treated with PC61 or control IgG every 4 days for four injections. A, Mean fluorescence staining intensity (MFI) of ANA at week 10. B, Severity score of immune complex-mediated glomerulonephritis at week 20. C, Serum level of IL-12p40 at week 20. Symbols represent one individual mouse and horizontal bar represents the mean value of serum level.

 
To determine whether Treg inactivation also leads to worsening of organ-specific autoimmunity, we performed extensive histological analysis of 96tm-Tg mice including lacrimal glands, sublingual glands, stomachs, thyroids, lungs, and sex organs (testicles, coagulating glands, or ovaries). We found significant gastritis in PC61-treated 96tm-Tg mice but not in PC61-treated WT mice nor in the control Ig-treated 96tm-Tg/WT mice, supporting once again that autoimmunity initiated by expression of cell surface gp96 can be potentiated by inactivating Treg (Fig. 6). Our finding is striking as it was reported that effective Treg deletion via day 3 thymectomy (d3Tx) led to accelerated dsDNA autoantibody response, but not the exacerbation of lupus glomerulonephritis in a lupus-prone mouse model (36, 37).


Figure 6
View larger version (47K):
[in this window]
[in a new window]

 
FIGURE 6. Autoimmune gastritis in 96tm- Tg mice but not WT mice after Treg inactivation. Mice were treated as in Fig. 5. A, Gastric histology of WT and 96tm-Tg mice after treatment with PC61 or control Ab. One representative mouse is shown for each group. B, Quantification of severity of gastritis. Each symbol represents one individual mouse with horizontal bar representing average value of severity.

 
TLR4-dependent hypersuppressiveness of 96tm-Tg Treg

We have shown recently that 96tm is a chaperone for TLR4, resulting in hyperresponsiveness of 96tm-expressing cells to LPS (25). We further demonstrated that TLR4 is critical for the onset of autoimmunity in 96tm-Tg mice. Because direct TLR4 engagement on Treg has been reported to enhance regulatory function of Treg (17), we hypothesized that the enhanced Treg activity in 96tm-Tg mice was the direct effect of increased chronic triggering of TLR4 due to 96tm expression on Treg. This hypothesis necessitates the expression of 96tm by Treg. As expected, we found that Tg Treg but not WT Treg expressed transcripts for 96tm (Fig. 7A). More importantly, we found that Treg from TLR4 null 96tm-Tg mice lost their superior ability to inhibit the proliferation of Teff (Fig. 7B), demonstrating that the increased suppression by 96tm-Tg Treg in comparison to WT Treg was mediated by TLR4. Our study is the first example of TLR4 hyperfunction in vivo in inducing increased Treg function to curtail TLR4-dependent autoimmunity.


Figure 7
View larger version (25K):
[in this window]
[in a new window]

 
FIGURE 7. TLR4 dependency for increased suppression by 96tm-Tg Treg. A, RT-PCR analysis for the expression of endogenous gp96, 96tm, and beta-actin mRNA from purified Treg and in vitro cultured bone marrow-derived macrophages (BMDM) of WT and 96tm-Tg origin B, In vitro suppression assay of Treg from WT, TLR4–/–, 96tm-TLR4+/–, or 96tm-TLR4–/– mice. WT Teff were stimulated with anti-CD3{epsilon} Ab plus WT APC in the presence of various Treg, as shown in Fig. 3. Two independent experiments were performed with similar results.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Enforced cell surface expression of a TLR-chaperone gp96, in the 96tm-Tg model, leads to breakdown of the immunological tolerance and the development of autoimmune diseases (24, 25). This process is dependent on TLR4, which is hyperfunctional as a result of the chaperone function of 96tm, but not the direct stimulation of TLR4 by 96tm (25). TLR4 activation has been implicated in regulating the function of Treg in vitro (17), although this conclusion remains controversial (14, 19, 21, 22, 23). The availability of 96tm-Tg mice allowed us to examine the impact of TLR4 hyperfunction on Treg in vivo. We found that the suppressive functions of Treg were increased in 96tm-Tg mice (Fig. 3); inactivation of Treg during the neonatal stage of life exacerbated both systemic and organ-specific autoimmune diseases (Figs. 5 and 6). By crossing 96tm-Tg mice into the TLR4 null background, we further discovered that the increased suppressive function of Treg was TLR4-dependent (Fig. 7). Our study has thus demonstrated that TLR4 hyperfunction can indeed lead to intensified Treg function without altering the development of Treg.

Thymectomy on day 3 has been widely used to investigate the roles of Treg in vivo. One enigma is that day 3 thymectomy leads to organ-specific rather than the systemic autoimmunity such as lupus. Depending upon mouse strain and gender, thymectomy on day 3 may induce inflammation in the stomach, thyroid, ovary, testicle, prostate, or other organs (38, 39). For example, C57BL/6 mice are resistant to the development of autoimmunity after thymectomy on day 3, including gastritis (38). Even in BALB/c mice that are more susceptible to day 3 thymectomy-induced gastritis (38, 40), inactivation of Treg is necessary but not sufficient to induce autoimmune gastritis (31). Yet, inactivation of Treg in our 96tm-Tg mice, which were in C57BL/6 background was sufficient to induce gastritis (Fig. 6), and exacerbate the systemic autoimmunity as indexed by the worsening of glomerulonephritis and earlier emergence of ANA (Fig. 5). Our finding demonstrated that Treg exerts a significant brake in the development of autoimmune diseases in 96tm-Tg mice. It offers a striking example that Treg can suppress both organ-specific and systemic autoimmunity in vivo.

The increased suppressive functions of Treg from 96tm-Tg mice were directly demonstrated in vitro (Fig. 3). Treg from Tg mice were able to exert much more suppression on the proliferation of either WT or Tg Teff regardless whether 96tm was expressed on APCs. Moreover, unlike WT mice that have age-dependent reduction of Treg activity (8, 26, 27), we found no decline of Tg Treg function with age (Fig. 3C). The increased Tg Treg function was also indirectly demonstrated in vivo, as we observed much more robust and systemic expansion and survival of SEA-specific Tg CD4+ T cells after the inactivation of Treg (Fig. 4).

Treg need to be activated before they can function. This requires IL-2 (5, 41) and costimulation, such as B7-CD28/CTLA-4 interaction (6, 42). Additional signals capable of regulating the Treg activity remain elusive. TLR are ancient molecules that detect microbial products and differentiate "non-self" from "self" (43). Engagement of TLRs with their ligands induces the activation of innate immunity. As a consequence, the TLR-induced proinflammatory environment can further promote the activation of the adaptive immunity (44). Recently, the roles of TLRs in regulating the functions of Treg have gained increasing attention (18). In response to LPS, mouse DCs produces IL-6, which is partially responsible for releasing Teff from Treg inhibition (16). In contrast, reversal of Treg function could be DC-independent (13). For example, TLR8 activation dampens the functions of Treg directly, which is dependent on MyD88-IRAK4 signaling pathway in the Treg autonomous fashion. Moreover, it has been shown that Treg selectively express TLR4 (17) and that interaction of Treg with LPS induces their suppressive function. In another study, TLR2 signaling was shown to promote the survival of CD4+CD25+ Treg as these cells were significantly decreased in TLR2–/– mice (45). More recently, heat shock protein 60 was reported to be able to enhance the function of human Treg in vitro via TLR2 in a manner that is dependent on both cell-cell contact and immunosuppressive cytokines IL-10 and TGF-beta (46). Our present work is consistent with the roles of TLR4 activation in directly enhancing Treg function (17, 18), providing a strong piece of in vivo evidence that excessive TLR activation could be counter-balanced by amplified Treg function.

Several unanswered questions remain. For example, what are the differences if any in the mechanisms of suppression between WT and Tg Treg? Our analyses so far have found no discernible distinctions between the two, including their ability to proliferate in vitro, the activation status measured by the level of CD3{zeta} chain phosphorylation, the cell surface marker of CD103 (47) (data not shown), and their cytokine profile in response to polyclonal activation (Fig. 2). Secondly, the number of Treg in WT and Tg is similar. The coordinated actions of Foxp3 and NFAT are critical for the development of Treg (4), yet it is unclear whether expression of gp96 on cell surface might affect this process qualitatively. Thirdly, there are many flavors of Treg in vivo (48). In particular, natural Foxp3+ Treg can be converted into inducible Treg in the presence of appropriate environment such as the presence of TGF-beta and IL-10. It is unclear whether these processes were in someway altered in 96tm-Tg mice.

In summary, we have shown that cell surface expression of a TLR-chaperone, gp96, induced lupus-like diseases and elevated Treg function without altering the development of CD4+CD25+ Foxp3+ Treg. Our study represents the first example of curtailing TLR4 hyperactivation via Treg on the organismal level to prevent systemic autoimmune diseases. Further studies into the mechanisms of this process in the context of infection, tissue injury, inflammation, and autoimmune pathology should be critical and fruitful in guiding the development of new immunotherapeutics against these conditions.


    Acknowledgments
 
We thank Drs. Leo Lefrançois, Mark Mamula, and Robert Clark for helpful discussions; Yi Yang and Matthew Staron (both from Dr. Zihai Li’s laboratory) for stimulating interactions during the course of the study as well as critical analysis of the data; and Dr. Mark Goldstein for reading and editing of the manuscript.


    Disclosures
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The authors have no financial conflict of interest.


    Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the National Institutes of Health Grants CA100191 (to Z.L.) and AI 42858 (to A.T.V.). Z.L. is a clinical scholar of the Leukemia and Lymphoma Society. Back

2 Address correspondence and reprint requests to Dr. Zihai Li, Center for Immunotherapy of Cancer and Infectious Diseases, Department of Immunology, University of Connecticut School of Medicine, Mail Code 1601, 263 Farmington Avenue, Farmington, CT 06030-1601. E-mail address: zli{at}up.uchc.edu Back

3 Abbreviations used in this paper: Treg, regulatory T cell; Teff, effector T cell; DC, dendritic cell; ANA, antinuclear Ab; GITR, glucocorticoid-induced TNFR; SEA, staphylococcal enterotoxin A; WT, wild type; Tg, transgenic. Back

Received for publication October 2, 2006. Accepted for publication December 8, 2006.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Sakaguchi, S.. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6: 345-352. [Medline]
  2. Shevach, E. M.. 2002. CD4+CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400. [Medline]
  3. Ziegler, S. F.. 2006. FOXP3: of mice and men. Annu. Rev. Immunol. 24: 209-226. [Medline]
  4. Wu, Y., M. Borde, V. Heissmeyer, M. Feuerer, A. D. Lapan, J. C. Stroud, D. L. Bates, L. Guo, A. Han, S. F. Ziegler, et al 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375-387. [Medline]
  5. Furtado, G. C., M. A. Curotto de Lafaille, N. Kutchukhidze, J. J. Lafaille. 2002. Interleukin 2 signaling is required for CD4+ regulatory T cell function. J. Exp. Med. 196: 851-857. [Abstract/Free Full Text]
  6. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440. [Medline]
  7. Bluestone, J. A., A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257. [Medline]
  8. Gregg, R. K., R. Jain, S. J. Schoenleber, R. Divekar, J. J. Bell, H. H. Lee, P. Yu, H. Zaghouani. 2004. A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J. Immunol. 173: 7308-7316. [Abstract/Free Full Text]
  9. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238. [Medline]
  10. Medzhitov, R.. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145. [Medline]
  11. Randow, F., B. Seed. 2001. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat. Cell Biol. 3: 891-896. [Medline]
  12. Pasare, C., R. Medzhitov. 2004. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21: 733-741. [Medline]
  13. Peng, G., Z. Guo, Y. Kiniwa, K. S. Voo, W. Peng, T. Fu, D. Y. Wang, Y. Li, H. Y. Wang, R. F. Wang. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309: 1380-1384. [Abstract/Free Full Text]
  14. Sutmuller, R. P., M. H. den Brok, M. Kramer, E. J. Bennink, L. W. Toonen, B. J. Kullberg, L. A. Joosten, S. Akira, M. G. Netea, G. J. Adema. 2006. Toll-like receptor 2 controls expansion and function of regulatory T cells. J. Clin. Invest. 116: 485-494. [Medline]
  15. Liu, H., M. Komai-Koma, D. Xu, F. Y. Liew. 2006. Toll-like receptor 2 signaling modulates the functions of CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 7048-7053. [Abstract/Free Full Text]
  16. Pasare, C., R. Medzhitov. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036. [Abstract/Free Full Text]
  17. Caramalho, I., T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, J. Demengeot. 2003. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197: 403-411. [Abstract/Free Full Text]
  18. Sakaguchi, S.. 2003. Control of immune responses by naturally arising CD4+ regulatory T cells that express Toll-like receptors. J. Exp. Med. 197: 397-401. [Free Full Text]
  19. Crellin, N. K., R. V. Garcia, O. Hadisfar, S. E. Allan, T. S. Steiner, M. K. Levings. 2005. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J. Immunol. 175: 8051-8059. [Abstract/Free Full Text]
  20. Gorczynski, R. M., Y. Kai, K. Miyake. 2006. MD1 expression regulates development of regulatory T cells. J. Immunol. 177: 1078-1084. [Abstract/Free Full Text]
  21. Kubo, T., R. D. Hatton, J. Oliver, X. Liu, C. O. Elson, C. T. Weaver. 2004. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J. Immunol. 173: 7249-7258. [Abstract/Free Full Text]
  22. Fehérvári, Z., S. Sakaguchi. 2004. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int. Immunol. 16: 1769-1780. [Abstract/Free Full Text]
  23. Komai-Koma, M., L. Jones, G. S. Ogg, D. Xu, F. Y. Liew. 2004. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl. Acad. Sci. USA 101: 3029-3034. [Abstract/Free Full Text]
  24. Liu, B., J. Dai, H. Zheng, D. Stoilova, S. Sun, Z. Li. 2003. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl. Acad. Sci. USA 100: 15824-15829. [Abstract/Free Full Text]
  25. Liu, B., Y. Yang, J. Dai, R. Medzhitov, M. A. Freudenberg, P. L. Zhang, Z. Li. 2006. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J. Immunol. 177: 6880-6888. [Abstract/Free Full Text]
  26. Tsaknaridis, L., L. Spencer, N. Culbertson, K. Hicks, D. LaTocha, Y. K. Chou, R. H. Whitham, A. Bakke, R. E. Jones, H. Offner, et al 2003. Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J. Neurosci. Res. 74: 296-308. [Medline]
  27. Matejuk, A., C. Hopke, A. A. Vandenbark, P. D. Hurn, H. Offner. 2005. Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy. J. Immunol. 174: 2387-2395. [Abstract/Free Full Text]
  28. Vella, A. T., J. E. McCormack, P. S. Linsley, J. W. Kappler, P. Marrack. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2: 261-270. [Medline]
  29. Maxwell, J. R., C. Ruby, N. I. Kerkvliet, A. T. Vella. 2002. Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity. J. Immunol. 168: 4372-4381. [Abstract/Free Full Text]
  30. Taguchi, O., T. Takahashi. 1996. Administration of anti-interleukin-2 receptor {alpha} antibody in vivo induces localized autoimmune disease. Eur. J. Immunol. 26: 1608-1612. [Medline]
  31. McHugh, R. S., E. M. Shevach. 2002. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol. 168: 5979-5983. [Abstract/Free Full Text]
  32. Zelenay, S., J. Demengeot. 2006. Comment on cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 177: 2036-2038. [Free Full Text]
  33. Stephens, L. A., S. M. Anderton. 2006. Comment on cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 177: 2036-2037. [Free Full Text]
  34. Kohm, A. P., J. S. McMahon, J. R. Podojil, W. S. Begolka, M. DeGutes, D. J. Kasprowicz, S. F. Ziegler, S. D. Miller. 2006. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J. Immunol. 176: 3301-3305. [Abstract/Free Full Text]
  35. Dai, J., B. Liu, D. Cua, and Z. Li. 2007. Essential roles of IL-12 and dendritic cells but not IL-23 and macrophages in lupus-like diseases initiated by cell surface Hsp gp96. Eur. J. Immunol. 37. In press.
  36. Bagavant, H., K. S. Tung. 2005. Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis. J. Immunol. 175: 944-950. [Abstract/Free Full Text]
  37. Bagavant, H., C. Thompson, K. Ohno, Y. Setiady, K. S. Tung. 2002. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int. Immunol. 14: 1397-1406. [Abstract/Free Full Text]
  38. Kojima, A., R. T. Prehn. 1981. Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics 14: 15-27. [Medline]
  39. Bonomo, A., P. J. Kehn, E. M. Shevach. 1995. Post-thymectomy autoimmunity: abnormal T-cell homeostasis. Immunol. Today 16: 61-67. [Medline]
  40. Suri-Payer, E., A. Z. Amar, R. McHugh, K. Natarajan, D. H. Margulies, E. M. Shevach. 1999. Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur. J. Immunol. 29: 669-677. [Medline]
  41. Thornton, A. M., E. E. Donovan, C. A. Piccirillo, E. M. Shevach. 2004. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J. Immunol. 172: 6519-6523. [Abstract/Free Full Text]
  42. Read, S., V. Malmstrom, F. Powrie. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302. [Abstract/Free Full Text]
  43. Janeway, C. A., Jr, R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216. [Medline]
  44. Iwasaki, A., R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995. [Medline]
  45. Netea, M. G., R. Sutmuller, C. Hermann, C. A. Van der Graaf, J. W. Van der Meer, J. H. van Krieken, T. Hartung, G. Adema, B. J. Kullberg. 2004. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J. Immunol. 172: 3712-3718. [Abstract/Free Full Text]
  46. Zanin-Zhorov, A., L. Cahalon, G. Tal, R. Margalit, O. Lider, I. R. Cohen. 2006. Heat shock protein 60 enhances CD4+CD25+ regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116: 2022-2032. [Medline]
  47. McHugh, R. S., M. J. Whitters, C. A. Piccirillo, D. A. Young, E. M. Shevach, M. Collins, M. C. Byrne. 2002. CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323. [Medline]
  48. Shevach, E. M.. 2006. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25: 195-201. [Medline]



This article has been cited by other articles:


Home page
Infect. Immun.Home page
Z. Ye, C. M. L. Lee, G. W. Sun, and Y.-H. Gan
Burkholderia pseudomallei Infection of T Cells Leads to T-Cell Costimulation Partially Provided by Flagellin
Infect. Immun., June 1, 2008; 76(6): 2541 - 2550.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A La Cava
T-regulatory cells in systemic lupus erythematosus
Lupus, May 1, 2008; 17(5): 421 - 425.
[Abstract] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dai, J.
Right arrow Articles by Li, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, J.
Right arrow Articles by Li, Z.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS